AVAILABLENot Applicable

Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid Tumors

United States

Plain-language summary

This study is an open-label, multicenter study for Continued Characterization of Safety and Tolerability of TT-00420 (tinengotinib) Tablet Monotherapy in Adult Patients with Advanced Solid Tumors

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Subject is currently enrolled in a pre-defined TransThera-sponsored parent study and is receiving tinengotinib as a single agent.
✓. Subject is currently deriving clinical benefit from the study treatment, as determined by the investigator.

Exclusion criteria

✕. Subject has been permanently discontinued from tinengotinib in the parent protocol for any reason other than enrollment in the Rollover study
✕. Subject does not meet the criteria specified in the parent protocol for continued treatment on study.

Trial details

NCT IDNCT06370013

SponsorTransThera Sciences (Nanjing), Inc.

Sponsor typeINDUSTRY

Study typeEXPANDED_ACCESS

Contact for this trial

Katie Hennessy, MS

267-627-0150 katie_hennessy@transtherabio.com

View on ClinicalTrials.gov More Advanced Solid Tumors trials